Acadian Asset Management’s Co-Diagnostics CODX Stock Holding History

Acadian Asset Management’s Portfolio CODX Stock Details CODX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-2,525	Closed	-$190K	–	1770
2022 Q4	$190K	Buy	+2,525	New	+$236K	﹤0.01%	1295
2022 Q3	–	Sell	-7,937	Closed	-$1.34M	–	1691
2022 Q2	$1.34M	Buy	7,937 +5,330	+204%	+$811K	0.01%	745
2022 Q1	$482K	Buy	2,607 +2,418	+1,279%	+$501K	﹤0.01%	1009
2021 Q4	$50K	Buy	+189	New	+$49.6K	﹤0.01%	1484

Other funds holding CODX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Acadian Asset Management's CODX Position: Q1 2023 in Review

Acadian Asset Management sold out of Co-Diagnostics (CODX) in Q1 2023, closing a stake of 2,525 shares — an estimated $190K sold.

Acadian Asset Management first reported a position in CODX in Q4 2021 and held it in 4 quarters. The position peaked at $1.34M in Q2 2022. 51 funds tracked by Wall St. Rank hold CODX as of Q1 2023.

Acadian Asset Management reported no remaining Co-Diagnostics position as of Q1 2023 after selling out during the quarter.
Acadian Asset Management sold 2,525 Co-Diagnostics shares in Q1 2023, an estimated $190K.
Acadian Asset Management first reported a position in Co-Diagnostics in Q4 2021 and held it in 4 quarters.
Acadian Asset Management's Co-Diagnostics position peaked at $1.34M in Q2 2022.
51 funds tracked by Wall St. Rank held Co-Diagnostics as of Q1 2023.

Based on Acadian Asset Management's 13F filing for Q1 2023, filed 11 May 2023.